| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | WZ4002 | CTRPv2 | pan-cancer | AAC | 0.17 | 9e-05 |
| mRNA | UNC0321 | CTRPv2 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | 0.21 | 0.0001 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.15 | 0.0001 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.23 | 0.0002 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.2 | 0.0002 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.14 | 0.0003 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.14 | 0.0003 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.21 | 0.0004 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0006 |